the SmallCapReview mailing list
A a specialty pharmaceutical company developing innovative
pharmaceutical products for use in men's and women's health using its
proprietary drug delivery technologies.
Lipocine’s clinical development pipeline includes three development
programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral
prodrug of testosterone containing testosterone undecanoate, is designed to
help restore normal testosterone levels in hypogonadal men. LPCN 1021 was
well tolerated and met the primary efficacy end-points in Phase 3 testing
with twice daily dosing. LPCN 1111, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for once-daily
dosing and is currently in Phase 2 testing. LPCN 1107, the potentially
first oral hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth, has been granted orphan drug
designation by the FDA. An End of Phase 2 meeting with the FDA has been
Hispanica International (HISP) revenues
for Q1 rose 400% to 649,411 from 129,871 during the comparable quarter the
previous year and will continue to increase from last year exponentially.
added over 1,400 retailers to now surpass 2,000 retail locations and will
expand to over 5,000 retail locations.
Hispanica Interantional is
engaged in the distribution of proprietary, licensed and third party
Hispanic and Ethnic food and beverages throughout the United States. HISP
has already begun to distribute fruit juices, nectars, and milk based
products and will begin to distribute teas, carbonated drinks, dry goods,
preserves, frozen foods and bakery products.
The brands distributed are done so on a
proprietary basis (through distribution agreements and/or exclusive
licensing arrangements). These brands emulate the flavors, tastes, and
traditions, which have been known for generations among the Hispanic and
other ethnic groups, and are now becoming part of the American mainstream
HISP is also committed in building long-term
relationships with its consumers by offering superior, high quality products
at the most competitive prices. HISP is headquartered in New York State with
distribution operations under way in the New York City Tri-State Region, the
Washington, D.C. Metro Area, the Houston Metropolitan Area, and in Los
Angeles and the Northern California Region.
personalized medicine company, that focuses on the development and marketing of
predictive, personalized, and prognostic medicine tests worldwide.
operates through two segments, Diagnostics and Other. The Diagnostics segment
primarily provides testing and collaborative development of testing that is
designed to assess an individuals risk for developing disease; identify a
patients likelihood of responding to drug therapy; guide a patients dosing to
ensure optimal treatment; and assess a patients risk of disease progression and
disease recurrence. The Other segment provides testing products and services to
the pharmaceutical, biotechnology, and medical research industries; and research
and development, and clinical services for patients. regulatory approvals.